Shandong Keyuan Pharmaceutical Co. Ltd. A (301281 SHE) stock market data APIs

Shandong Keyuan Pharmaceutical Co., Ltd. is involved in the research and development, manufacture, and marketing of active pharmaceutical ingredients. It offers gliclazide, for the treatment of NIDDM; metformin hydrochloride used as an adjunct to diet and exercise in adult patients with NIDDM; isosorbide mononitrate for prevention of angina pectoris and treatment of acute and chronic angina pectoris, hypertension, and myocardial infarction; isosorbide dinitrate to prevent angina pectoris due to coronary artery disease; mecobalamin for peripheral neuropathies; lansoprazole to treat acid-reflux disorders, peptic ulcer disease, h. pylori eradication, and prevention of gastrointestinal bleeds; ropivacaine hydrochloride for obstetric and regional anesthesia; isoflurane; fluoxetine hydrochloride, an anti-depression drug; clemastine fumarate, an anti-allergic agent; isoprenaline hydrochloride to treat mild or transient episodes of heart block; esmolol hydrochloride for the rapid control of ventricular rate; xanthinol nicotinate to treat of brain function barrier, cerebral embolism and cerebral thrombosis; amlexanox for treatment of aphthous ulcers; nisolsipine for hypertension; clarithromycin lactobionate; trepibutone; propafenone hydrochloride; diclofenac potassium to treat osteoarthritis and rheumatoid arthritis; chlorzoxazone for relief of discomfort associated with acute painful musculoskeletal conditions; esomeprazole sodium treats related gastric ulcer disease and zollinger-ehrlich syndrome; palonosetron hydrochloride, a chemotherapy adjuvant medication; edaravone, a cerebral protective agent; vildagliptin to treat diabetes; etamsylate, a hemostatic medication; pranoprofen that is a non-steroidal anti-inflammatory analgesic and antipyretic drugs; parecoxib sodium; and lurasidone hydrochloride, a medication for schizophrenia. The company was incorporated in 2004 and is headquartered in Jinan, China.